BGP-15 (C005B-100627)

General description

BGP-15 is a hydroxylamine derivative, which has cytoprotective and neuroprotective properties. It reduces phospho- c-Jun N-terminal kinase (pJNK) and p38 stress signalling. BGP-15 also stimulates non-specific serine/threonine protein kinase (AKT) and insulin-like growth factor 1 receptor (IGFR1) protective signalling. BGP-15 functions as an insulin sensitizer in an olanzapine-induced metabolic disorder. It protects cells against cell death and enhances the expression of heat shock protein (HSP). BGP-15 might be used to treat heart failure (HF) and atrial fibrillation (AF).

Application

BGP-15 has been used to study its influence on proteasomal degradation of missense dystrophins.

Biochem/physiol Actions

BGP-15 is PARP inhibitor, HSP72 activator.

Molecular Weight: 351.27. Empirical Formula: C₁₄H₂₂N₄O₂· 2HCl. Quality Level: 100. Assay: ≥. 98% (HPLC). form: solid. solubility: deionized water: 28 . mg/mL. storage temp.: −. 20°C. SMILES string: Cl.Cl.N\C(: N/OCC(O)CN1CCCCC1)c2cccnc2. InChI: 1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18. . /h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17). 2*1H. InChI key: ISGGVCWFTPTHIX-UHFFFAOYSA-N. Pictograms: GHS06. Signal Word: Danger. Hazard Statements: H301. Precautionary Statements: P264 - P270 - P301 + P310 - P405 - P501. Hazard Classifications: Acute Tox. 3 Oral. Storage Class Code: 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects. WGK: WGK 3. Flash Point(F): Not applicable. Flash Point(C): Not applicable.